An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

NCT04189614 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Cofetuzumab Pelidotin

Sponsor

AbbVie

Collaborators

[object Object]